NeuroMetrix, Inc.
NURO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.02 | -0.01 | -0.75 |
| FCF Yield | -91.15% | -167.20% | -50.01% | -2.14% |
| EV / EBITDA | -0.74 | -0.32 | -1.43 | -36.57 |
| Quality | ||||
| ROIC | -60.91% | -35.17% | -19.65% | -9.21% |
| Gross Margin | 55.38% | 66.89% | 69.65% | 71.75% |
| Cash Conversion Ratio | 0.91 | 0.93 | 1.20 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.38% | -10.58% | 3.82% | -3.81% |
| Free Cash Flow Growth | -13.72% | -17.99% | -140.89% | -6.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.21 | 0.83 | 10.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.00 | 1.25 | 1.55 | 3.30 |
| Cash Conversion Cycle | 288.69 | 283.13 | 210.22 | 79.88 |